Ian Longacre

Associate

  • JD, Emory University School of Law, 2014; TIGER (Technological Innovation Generating Economic Results) certificate in intellectual property law and entrepreneurship; Graduate Student Government Association, Vice President of Finance
  • MA (Psychology, Neuroscience & Animal Behavior Program), Emory University, 2010
  • BS (Psychology), magna cum laude, East Tennessee State University, 2007; Top Senior in Major

Qualifications

  • Massachusetts, 2014
  • U.S. Patent and Trademark Office, 2015

Ian Longacre

Associate

Ian Longacre is an associate in the intellectual property transactions group. His practice focuses on representing biotechnology, pharmaceutical, and medical device companies in all manner of transactions involving technology and intellectual property, including: research, development and commercialization collaborations; licensing; joint ventures; mergers and acquisitions; supply, distribution and co-promotion relationships; and other strategic commercial transactions.

Prior to joining the firm in 2020, Ian was an associate in the intellectual property transactions group in the Boston office of another premier international law firm. 

Experience

  • Represented Dragonfly Therapeutics in its license agreement with Bristol-Myers Squibb who will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, for an upfront payment of $475 million.*
  • Represented Vedere Bio, Inc., a novel optogenetics AAV gene therapy company, in its acquisition by Novartis for $150 million upfront and up to $280 million in total, and the spin out of certain earlier-stage vision restoration and preservation assets into a newly formed entity – Vedere Bio II, Inc.*  
  • Represented Teva Pharmaceutical Industries Ltd. in its exclusive license and development agreement with Alvotech Hf, under which Teva receives exclusive rights of commercialization in the U.S. of five biosimilar product candidates. The originator products of these five candidates currently generate around $35 billion in U.S. sales.*
  • Represented EQRx in its strategic collaboration and license agreement with Hansoh Pharmaceutical Group Company Limited, under which EQRx receives the exclusive right under certain patents and know-how to discover, research, develop and commercialize Hansoh’s compound almonertinib worldwide outside of Greater China.* 
  • Represented EQRx in its strategic collaboration and license agreement with G1 Therapeutics, under which EQRx receives the exclusive right under certain patents and know-how to discover, research, develop and commercialize G1’s compound lerociclib worldwide outside of the Asia-Pacific region (excluding Japan).*
  • Represented Dragonfly Therapeutics in its exclusive research and collaboration agreement with Bristol-Myers Squibb to develop Dragonfly’s novel immunotherapies for multiple sclerosis and neuro-inflammation targets, for an upfront payment of $55 million.*
  • Represented Dragonfly Therapeutics in its research collaboration with AbbVie to advance a number of Dragonfly’s novel NK cell engager-based immunotherapies for autoimmune and oncology indications, for an upfront payment, future success-based milestone payments and royalties.* 
  • Represented Skyhawk Therapeutics, Inc. in a number of strategic collaboration agreements with big pharma partners relating to the out-licensing of Skyhawk’s proprietary SkySTAR technology for the discovery, development and commercialization of small molecules that correct RNA splicing. Big pharma partners include Merck, Genentech (a member of the Roche Group), Celgene Corporation, Takeda Pharmaceutical Company Limited, and Biogen, and target areas of therapy include oncology, and neuro, autoimmune, and metabolic diseases.*  
  • Represented Galapagos NV with MorphoSys AG in global license with Novartis Pharma for developing and commercializing their joint program MOR106 to treat inflammatory diseases, valued up to 850 million.*
  • Represented Orionis Biosciences on its major drug discovery collaboration with Novartis, to discover and design novel small molecule therapeutics, such as protein degraders, across various therapeutic areas, by broadly leveraging Orionis’ Allo-Glue™ technology platform.*

*Experience prior to joining Ropes & Gray

 

Publications

  • Michael T. Williams, Matthew R. Skelton, Ian D. Longacre, Kimberly N. Huggins, Amanda M. Maple, Charles V. Vorhees, Russel W. Brown, “Neuronal Reorganization in Adult Rats Neonatally Exposed to (+)-3,4- Methylenedioxymethamphetamine,” Toxicology Reports, Volume 1 (Supplement C). 699-706. (January 2014)
  • Marla K. Perna, Zackary A. Cope, Amanda M. Maple, Ian D. Longacre, Jennifer A. Correll, Russell W. Brown, “Nicotine sensitization in adult male and female rats quinpirole-primed as neonates,” Psychopharmacology, 199(1):67-75. (July 2008)
  • JD, Emory University School of Law, 2014; TIGER (Technological Innovation Generating Economic Results) certificate in intellectual property law and entrepreneurship; Graduate Student Government Association, Vice President of Finance
  • MA (Psychology, Neuroscience & Animal Behavior Program), Emory University, 2010
  • BS (Psychology), magna cum laude, East Tennessee State University, 2007; Top Senior in Major

Qualifications

  • Massachusetts, 2014
  • U.S. Patent and Trademark Office, 2015
Cookie Settings